ETFsBloomberg Emerging Markets USD Sovereign Index
Invesco

Invesco Emerging Markets USD Bond UCITS ETF Dist

EMSB XETRAIrelandNot PEA-eligible
Last close · EUR
14.22EUR
0.00% · +€0.00
Published closes: 4 Nov 2026 - 5 Nov 2026
5 Nov 2026, close
EMSBBase
Fund charges
0.25%PRIIPs ongoing costs
Fund size
€60.8Mall share classes
Return 1Y
+3.0%Index +11.4%
Sharpe 3Y
0.59Index 0.93
Volatility 1Y
5.5%annualised
Holdings
422Fund holdings

Performance

Compare
  • EMSB+3.0%
  • Price, EUR

Returns

Returns1M3M6MYTD1Y3Y5Y
EMSB+2.2%+0.9%+3.0%+4.0%+3.0%+23.2%-
MSCI Emerging Markets IMI-13.6%-7.4%-5.4%+13.0%+11.4%+56.7%+38.4%
Gap to MSCI Emerging Markets IMI+15.7%+8.2%+8.5%-9.0%-8.5%-33.4%-

Risk and return

Sharpe ratio · 3Y
0.59
Below MSCI Emerging Markets IMI · 0.93
Return p.a.
+7.3%
Volatility
7.8%
Max loss
-12.4%Apr 2025

Sharpe vs indices

MSCI World
1.24
S&P 500
1.21
STOXX Europe 600
1.04
MSCI Emerging Markets IMI
0.93
EMSB
0.59
CAC 40
0.37
Method

Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.

Top holdings

Top 10
6.4%
Holdings
422
As of
Fund holdings
  1. 1ARGENTINA 4.125% 09/07/35US040114HT091.07%
  2. 2Eagle Funding Luxco Sarl 5.5% 17/08/30USL2660VAA371.03%
  3. 3ARGENTINA 0.75% 09/07/30US040114HS260.75%
  4. 4ARGENTINA 5% 09/01/38US040114HU710.67%
  5. 5SAUDI INTERNATIONAL BOND 5.75% 16/01/54XS27475995090.53%
  6. 6ARGENTINA 3.5% 09/07/41US040114HV540.50%
  7. 7QATAR 4.817% 14/03/49XS19593377490.49%
  8. 8ECUADOR 6.9% 31/07/35XS22142384410.46%
  9. 9QATAR 4.4% 16/04/50XS21553527480.46%
  10. 10OMAN GOV INTERNTL BOND 6% 01/08/29XS19444127480.45%

Countries

Not published · Country classification unavailable

Market cap

Weight vs holdings

6.4%of the fund sits in the top 10 holdings
  • Holdings 1-10
  • Holdings 11-50
  • Holdings 51-200
  • Holdings 201+

Size split

Not published

Compare ETFs in Copio.

ETF comparison in the Copio app, showing costs and returns with illustrative data.

Factual research, without a suitability score or investment recommendation. Past relationships can change.